Danatlas is a clinical-stage biopharmaceutical leader developing novel therapies targeting synthetic lethal mechanisms in DNA damage repair pathways. Headquartered in Beijing with a U.S. subsidiary in Boston, we pioneer precision medicines addressing unmet needs in breast, gynecological, gastrointestinal, and genitourinary cancers through transformative .

Our integrated platform combines drug discovery, preclinical development, translational medicine, and clinical research capabilities. Supported by a multinational team and strategic partnerships, we accelerate the development of biomarker-driven therapies from concept to clinic.

With multiple core programs advancing through clinical trials and IND-enabling studies, we are establishing a differentiated pipeline targeting treatment-resistant solid tumors. Danatlas is committed to becoming the cornerstone of next-generation precision oncology, delivering new hope for patient health and longevity.